高通量测序鉴定蛤蚧定喘丸生物原料
对3份参考和9份市售样品检测显示,所有处方生物成分均被检出,蛤蚧为优势成分,相对丰度50.5%-98.07%,麦冬在多数样品中相对丰度仅0.001%-0.003%,同时检出潜在掺伪物和污染物。
要点
- 市售样品中蛤蚧相对丰度50.5%-98.07%,麦冬相对丰度0.001%-0.003%。
- 方法可检出非处方物种如Calotes wangi、黄芪及曲霉、青霉等真菌。
核心结论
- 整合条形码与HTS的流程为复杂中成药的分子谱分析提供了敏感框架。
- 在将非处方序列检测转化为监管或安全性结论前,需要实证定义解释标准。
研究设计与样本
- 研究从3份参考和9份市售蛤蚧定喘丸样品中提取总DNA。
- 采用16S rRNA(动物源)和ITS2(植物源)条形码结合形态学鉴定,建立专用参考数据库。
- 通过高通量测序获得41,918,610条高质量reads,产生5103个OTU。
主要发现
- 5103个OTU中,2798个归属动物源材料,2305个归属植物源材料。
- 所有样品覆盖度均超过0.9995,稀释曲线、Shannon-Wiener曲线和物种累积曲线均达到平台期。
- 蛤蚧为优势成分,相对丰度50.5%-98.07%;麦冬在多数样品中相对丰度0.001%-0.003%。
- 检出潜在掺伪物和污染物,包括Calotes wangi、黄芪、Bothus robinsi及曲霉、青霉等真菌。
关键数值与推荐
- 所有样品覆盖度值超过0.9995,测序深度足以捕获大部分物种多样性。
- 蛤蚧相对丰度范围为50.5%-98.07%,麦冬相对丰度范围为0.001%-0.003%。
临床怎么用
- 该HTS流程可用于蛤蚧定喘丸处方生物原料的同时鉴定和掺伪监测。
- 检出非处方序列时,需谨慎解释,不宜直接作为监管或安全性结论。
局限性
- 部分非处方物种在经Sanger测序验证的原料自制备参考样品中也被检出。
- 在将非处方序列检测转化为监管或安全性结论前,需要实证定义解释标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Gejie Dingchuan Wan (GDW), a classical prescription comprising fourteen ingredients, including twelve biological materials and two mineral components, is used to nourish yin, clear the lung, and relieve asthma and vulnerable to adulteration, yet a systematic molecular method for simultaneously authenticating all prescribed biological ingredients is lacking. AIM OF THE STUDY: To optimize key technical steps, including DNA extraction and barcode selection, for mixed samples containing both animal- and plant-derived medicinal materials; and to establish an HTS-based method for identifying the raw medicinal materials in GDW. MATERIALS AND METHODS: Total DNA was extracted from three reference and nine commercial GDW samples. An integrated DNA barcoding strategy (16S rRNA for animal-derived materials and ITS2 for plant-derived materials) combined with morphological identification, and all sequences were deposited in GenBank to establish a dedicated reference database. OTUs were assigned taxonomically against custom reference databases. Diversity indices and statistical analyses were calculated. RESULTS: 41,918,610 high-quality reads were generated, yielding a total of 5103 operational taxonomic units (OTUs), including 2798 assigned to animal-derived materials and 2305 assigned to plant-derived materials. Assessment of potential technical biases showed that all samples had coverage values exceeding 0.9995, while the rarefaction, Shannon-Wiener, and species accumulation curves all reached plateaus, indicating that the sequencing depth was sufficient to capture most of the species diversity. All twelve prescribed biological components were detected in both reference and commercial samples. Gecko was the dominant component, accounting for 50.5%-98.07% relative abundance, while Ophiopogonis Radix was rarely detectable in most samples, with relative abundance ranging from 0.001% to 0.003%. In addition to the prescribed ingredients, HTS also detected sequences corresponding to potential adulterants and contaminants, highlighting the utility of this approach for adulteration surveillance. These non-prescribed taxa included Calotes wangi (a known adulterant of Gecko), Astragalus membranaceus, Bothus robinsi, and various fungal species, including Aspergillus and Penicillium. Notably, some of these taxa were detected not only in commercial samples but also in self-prepared reference samples formulated from raw materials that had been previously authenticated by Sanger sequencing. While 16S rRNA and ITS2 were effective for verifying the identity of individual raw materials, HTS revealed a broader spectrum of DNA sequences present in the finished products, including both prescribed and non-prescribed taxa. CONCLUSION: The integrated barcoding-HTS pipeline provides a sensitive framework for molecular profiling of complex Chinese patent medicines and highlights the need for empirically defined interpretive criteria before detections of non-prescribed sequences can be translated into regulatory or safety conclusions.
引用
- Huang Q, Jing X, Chen G, et al. Identification of biological raw materials in Chinese patent medicine Gejie Dingchuan Wan using high-throughput sequencing. J Ethnopharmacol. 2026. PMID: 42419401. doi:10.1016/j.jep.2026.122173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。